Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Greg Schreiner, the pianist, narrator and producer of Hollywood Revisited, will present “Out of the Closet and Into the Day — ...

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rockwall ISD sixth grade SAGE students recently participated in a “Pathways to Success” field trip where they had the ...

From consumer to tech, here's a list of key deals reported this week: Molson Coors Beverage (TAP) has agreed to acquire an 8.5% stake in Fevertree Drinks, becom ...

In its 10th year, SAGE opened its "My Hometown" photography show to anyone with a phone camera, stipulating any photo ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...